These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 283721)

  • 81. How effective is LAAM treatment? Clinical comparison with methadone.
    Zangwell BC; McGahan P; Dorozynsky L; McLellan AT
    NIDA Res Monogr; 1986; 67():249-55. PubMed ID: 3092073
    [No Abstract]   [Full Text] [Related]  

  • 82. Plasma testosterone and luteinizing hormone levels during levo-alpha-acetylmethadol maintenance and withdrawal.
    Mendelson JH; Ellingboe J; Judson BA; Goldstein A
    Clin Pharmacol Ther; 1984 Apr; 35(4):545-7. PubMed ID: 6705455
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Levo-alpha-acetylmethadol (LAAM) induced QTc-prolongation - results from a controlled clinical trial.
    Wieneke H; Conrads H; Wolstein J; Breuckmann F; Gastpar M; Erbel R; Scherbaum N
    Eur J Med Res; 2009 Jan; 14(1):7-12. PubMed ID: 19258204
    [TBL] [Abstract][Full Text] [Related]  

  • 84. A clinical, controlled study of l-alpha-acetylmethadol in the treatment of narcotic addiction.
    Marcovici M; O'Brien CP; McLellan AT; Kacian J
    Am J Psychiatry; 1981 Feb; 138(2):234-6. PubMed ID: 7457647
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Can the community be protected against the hazards of take-home methadone? 1974 [proceedings].
    Goldstein A; Judson B
    NIDA Res Monogr; 1976 Jul; (8):62-3. PubMed ID: 792698
    [No Abstract]   [Full Text] [Related]  

  • 86. Pharmacodynamics of LAAM in man: plasma levels of LAAM and its metabolites following acute and chronic administration in man (fourth and sixth quarter progress reports). 1974-5 [proceedings].
    Henderson GL
    NIDA Res Monogr; 1976 Jul; (8):64-5. PubMed ID: 995181
    [No Abstract]   [Full Text] [Related]  

  • 87. Failure of acetylmethadol in treatment of narcotic addicts due to nonpharmacologic factors.
    Segal R; Everson A; Sellers EM; Thakur R
    Can Med Assoc J; 1976 Nov; 115(10):1014-6. PubMed ID: 1032578
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Failure of methadone and levomethadyl acetate (levo-alpha-acetylmethadol, LAAM) maintenance to affect memory.
    Grevert P; Masover B; Goldstein A
    Arch Gen Psychiatry; 1977 Jul; 34(7):849-53. PubMed ID: 879977
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Heroin and chromosome damage.
    Falek A; Hollingsworth F
    Arch Gen Psychiatry; 1980 Feb; 37(2):227-8. PubMed ID: 7352852
    [No Abstract]   [Full Text] [Related]  

  • 90. Levo-alpha-acetylmethadol (LAAM): clinical, research, and policy issues of a new pharmacotherapy for opioid addiction.
    Prendergast ML; Grella C; Perry SM; Anglin MD
    J Psychoactive Drugs; 1995; 27(3):239-47. PubMed ID: 8594167
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Torsades de pointes associated with high dose levomethadyl acetate (ORLAAM).
    Deamer RL; Wilson DR; Clark DS; Prichard JG
    J Addict Dis; 2001; 20(4):7-14. PubMed ID: 11760927
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Induction with levomethadyl acetate: safety and efficacy.
    Jones HE; Strain EC; Bigelow GE; Walsh SL; Stitzer ML; Eissenberg T; Johnson RE
    Arch Gen Psychiatry; 1998 Aug; 55(8):729-36. PubMed ID: 9707384
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Levo-alpha-acetylmethadol (LAAM) versus methadone maintenance: 1-year treatment retention, outcomes and status.
    Anglin MD; Conner BT; Annon J; Longshore D
    Addiction; 2007 Sep; 102(9):1432-42. PubMed ID: 17697277
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Levo-Alpha Acetyl Methadol (LAAM). Its advantages and drawbacks.
    Finn P; Wilcock K
    J Subst Abuse Treat; 1997; 14(6):559-64. PubMed ID: 9437627
    [TBL] [Abstract][Full Text] [Related]  

  • 95. 1-alpha-acetylmethadol(LAAM) pharmacokinetics and metabolism: current status.
    Misra AL; Mulé SJ
    Am J Drug Alcohol Abuse; 1975; 2(3-4):301-5. PubMed ID: 818895
    [No Abstract]   [Full Text] [Related]  

  • 96. Methadone vs. L-alpha-acetylmethadol (LAAM) in the treatment of opiate addiction. A meta-analysis of the randomized, controlled trials.
    Glanz M; Klawansky S; McAullife W; Chalmers T
    Am J Addict; 1997; 6(4):339-49. PubMed ID: 9398932
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Longitudinal effects of LAAM and methadone maintenance on heroin addict behavior.
    Anglin MD; Conner BT; Annon JJ; Longshore D
    J Behav Health Serv Res; 2009 Apr; 36(2):267-82. PubMed ID: 19023658
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Relative potency of levo-alpha-acetylmethadol and methadone in humans under acute dosing conditions.
    Eissenberg T; Stitzer ML; Bigelow GE; Buchhalter AR; Walsh SL
    J Pharmacol Exp Ther; 1999 May; 289(2):936-45. PubMed ID: 10215673
    [TBL] [Abstract][Full Text] [Related]  

  • 99. 1-Alpha-acetylmethoadol in the treatment of opiate addiction: progress report. 1971 [proceedings].
    Blachly PH
    NIDA Res Monogr; 1976 Jul; (8):55-6. PubMed ID: 995177
    [No Abstract]   [Full Text] [Related]  

  • 100. Pharmacologic treatments for heroin and cocaine dependence.
    Kleber HD
    Am J Addict; 2003; 12(s2):S5-S18. PubMed ID: 12857659
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.